StockNews.com Initiates Coverage on Senseonics (NYSE:SENS)

Research analysts at StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 target price on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Stock Performance

NYSE SENS opened at $0.35 on Wednesday. Senseonics has a 1-year low of $0.32 and a 1-year high of $0.75. The business’s 50-day simple moving average is $0.37 and its 200-day simple moving average is $0.41. The firm has a market capitalization of $187.40 million, a P/E ratio of -2.69 and a beta of 0.79. The company has a debt-to-equity ratio of 59.17, a current ratio of 3.11 and a quick ratio of 2.89.

Senseonics (NYSE:SENS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. The business had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.86 million. Equities analysts predict that Senseonics will post -0.13 EPS for the current year.

Institutional Trading of Senseonics

Hedge funds have recently bought and sold shares of the company. State Board of Administration of Florida Retirement System purchased a new position in Senseonics in the first quarter valued at about $91,000. Virtu Financial LLC acquired a new position in Senseonics in the 1st quarter valued at approximately $162,000. Cubist Systematic Strategies LLC lifted its position in Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after acquiring an additional 51,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Senseonics by 30.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after purchasing an additional 211,128 shares during the period. 12.36% of the stock is owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.